TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05611489

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open appendectomy
Description: performed With the patient in supine position.incision made lateral to McBurney's point.layers of the abdomen is exposed. If the cecum can be visualized, it can be mobilized and used to identify the appendix. Once the appendix is identified, the mesoappendix should be dissected and the appendiceal vessels divided between clamps. The appendiceal vessels are then ligated with silk sutures. A silk purse-string suture can then be placed around the appendiceal base.A 15-blade knife is then used to excise the appendix proximal to the right angle clamp.The appendiceal stump mucosa can be obliterated using electrocautery. Then good haemostasis and layered closure is done.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Lap appendectomy
Description: Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
Study: NCT05288777

Intervention type: DRUG
Group type: OTHER
Intervention: T-DM1
Description: Dosed at 3.6 mg/kg of body weight every 3 weeks for Her2/neu+ patients for a total duration of 14 cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: T-DM1
Description: Dosed at 3.6 mg/kg of body weight every 3 weeks for Her2/neu+ patients for a total duration of 14 cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Dosed at 825 mg/m2 +/- 150mg twice per day for a total duration of 6 months

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Dosed at 825 mg/m2 +/- 150mg twice per day for a total duration of 6 months

Intervention type: RADIATION
Group type: OTHER
Intervention: External Beam Radiation Therapy 0
Description: Dose of 40 Gy in 15 fractions to the whole breast or chest wall followed by consideration of a 10 Gy in 4 fraction boost to the lumpectomy cavity for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.

Intervention type: RADIATION
Group type: OTHER
Intervention: External Beam Radiation Therapy 0
Description: Dose of 40 Gy in 15 fractions to the whole breast or chest wall followed by consideration of a 10 Gy in 4 fraction boost to the lumpectomy cavity for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.

Intervention type: RADIATION
Group type: OTHER
Intervention: External Beam Radiation Therapy 1
Description: Dose of 40 Gy in 15 fractions to either the breast or chest wall along with comprehensive nodal radiation followed by consideration of a 10 Gy in 4 fraction boost for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.

Intervention type: RADIATION
Group type: OTHER
Intervention: External Beam Radiation Therapy 1
Description: Dose of 40 Gy in 15 fractions to either the breast or chest wall along with comprehensive nodal radiation followed by consideration of a 10 Gy in 4 fraction boost for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
Study: NCT05182970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Individualised target dose of 2000 mg daily depending on tolerability.
Study: NCT06152523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab/MEDI5257
Description: Phase II trial using an A'Hern design with a safety lead-in cohort to assess the safety/tolerability of the combination of monalizumab and MEDI5752 in patients with metastatic MSI/dMMR cancer
Study: NCT05622890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
Study: NCT05624086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Hepatitis-C Men With Sexual Dysfunction (erectile dysfunction) Complaint will receive exercise-training sessions (one hour walking on treadmill, for 3 months, three walking sessions per the week)
Study: NCT04947826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC (Hepatic arterial infusion chemotherapy)
Description: For the HAIC procedure, a 5F catheter was introduced using the Seldinger technique through the femoral artery or the radial artery. Then, angiographic surveys of the celiac trunk and superior mesenteric artery were performed. According to tumor size, location, and arterial supply, the catheter or a 2.7F microcatheter was advanced into the hepatic artery at the level of selective segmental, lobar, or whole liver. The catheter or microcatheter was connected to an external infusion pump. The following regimen of modified FOLFOX was administered: oxaliplatin, 85mg/m2 for 2 hours; leucovorin, 400mg/m2; and 5-fluorouracil, 2400mg/m2 for 44-46 hours. After HAIC treatment, the catheter or microcatheter, and the sheath were removed.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: HAIC (Hepatic arterial infusion chemotherapy)
Description: For the HAIC procedure, a 5F catheter was introduced using the Seldinger technique through the femoral artery or the radial artery. Then, angiographic surveys of the celiac trunk and superior mesenteric artery were performed. According to tumor size, location, and arterial supply, the catheter or a 2.7F microcatheter was advanced into the hepatic artery at the level of selective segmental, lobar, or whole liver. The catheter or microcatheter was connected to an external infusion pump. The following regimen of modified FOLFOX was administered: oxaliplatin, 85mg/m2 for 2 hours; leucovorin, 400mg/m2; and 5-fluorouracil, 2400mg/m2 for 44-46 hours. After HAIC treatment, the catheter or microcatheter, and the sheath were removed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10 (PD-1 antibody)
Description: PD-1 antibody with proven efficacy in advanced hepatocellular carcinoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04 (VEGF antibody)
Description: Combination of PD-1 antibody and VEGF antibody might promote the efficacy of HAIC in hepatocellular carcinoma with major portal vein thrombosis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06446999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga-Based Breathing Exercise
Description: Breathing Exercise Protocol Purpose: This protocol is a guide prepared for patients who agree to participate in the study within the scope of scientific research to do breathing exercises.~Materials Required: A comfortable chair/a comfortable bed to lie on and comfortable clothing.~Exercise Duration: Approximately 20 minutes Exercise Time and Frequency: It should be done twice a day, at the same time, in the morning and in the evening.~You can do the exercise before going for a walk in the corridor in the morning and before going to sleep in the evening.~Normal Breathing and Focusing on Breathing (3 minutes) Alternate Nose Breathing-Nadi Shodhana (15-20 times/6 minutes) Normal Breathing and Focusing on Breathing (3 minutes) Bhramari Pranayama-Bee Buzzing Sound(8-10 times/5 minutes) Normal Breathing and Focusing on Breathing (3 minutes)
Study: NCT06308731

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine-Based Energy Drink
Description: Energy drink with 200 mg caffeine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05561751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GPC-100
Description: GPC-100 is to be administered at a dose of 3.14 mg/kg GPC-100 free base via IV infusion. The corresponding volume of the reconstituted GPC-100 solution calculated based on the patient weight will be administered via IV infusion over 15 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GPC-100
Description: GPC-100 is to be administered at a dose of 3.14 mg/kg GPC-100 free base via IV infusion. The corresponding volume of the reconstituted GPC-100 solution calculated based on the patient weight will be administered via IV infusion over 15 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: propranolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: propranolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF
Study: NCT06397950

Intervention type: OTHER
Intervention: Assessment of potential fatigue factors
Description: 3 visits will be carried out: V0: Inclusion V1: Familiarization visit V2: Experimental visit~V1~* Completion of MFI-20 questionnaire for familiarisation.~* Information about accelerometry and activity journal use will be delivered to the patient.~* The participant will be equipped with an accelerometer and asked to complete the activity journal for seven days.~V2~* Completion of questionnaires: MFI-20, GATS tobacco consumption questionnaire, caffeine consumption questionnaire, Fatigue Catastrophizing Scale, PSQI.~* Assessment of cognitive function: Sustained Attention to Response Task (SART), AX-Continuous Performance Task (AX-CPT) and verbal fluency test (animals and P categories).~* Assessment of physical evaluation: isometric evaluation of maximal handgrip strength, one-minute sit-to-stand test, isometric evaluation of maximal quadriceps strength, QIF test.~Negative symptoms will be assessed. Calf circumference will be measured for sarcopenia risk.
Study: NCT04822337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
Description: Phase I - Chemotherapy multiple agents systemic Phase II - Maximum Tolerated Dose from Phase I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
Description: Phase I - Chemotherapy multiple agents systemic Phase II - Maximum Tolerated Dose from Phase I
Study: NCT05082233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280 tablets
Description: Treatment group A:SHR7280 tablets ; 300mg BID； Treatment group B:SHR7280 tablets ; 200mg BID； Treatment group C:SHR7280 tablets ; 200mg QD； Treatment group D:SHR7280 tablets ; 400mg BID；
Study: NCT05278065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at weekly assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose commercially available e-liquid flavors (tobacco) at each weekly assessment.
Study: NCT06431295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FaceScan
Description: Digital visual acuity device built for iOS (iPhone) that conducts an assessment of visual acuity using a combination of integrated light detection and ranging (LiDAR) and voice processing.
Study: NCT05354557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Patients will receive 12 cycles of iberdomide as maintenance therapy. Cohort 1: Cycle 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles Cohort 2: Cycles 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Patients will receive 12 cycles of iberdomide as maintenance therapy. Cohort 1: Cycle 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles Cohort 2: Cycles 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles
Study: NCT05940493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT04673799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MV088 injection
Description: MV088 injection (60mg) by subcutaneous injection once on the first day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia® injection
Description: Prolia® injection (60mg) by subcutaneous injection once on the first day
Study: NCT05304221

Intervention type: OTHER
Intervention: Shamir Resistance Calculator
Description: An on-line calculator which is free and accessible from all devices, which may predict the risk of MDRO infection upon admission, and the risk of nosocomial XDRO infection during the hospitalization.~The calculator contains only parameters that could be extracted bedside, at the first presentation of a septic patient, including the ability to conduct a complete assessment also among patients with reduced consciousness and/or cognition.
Study: NCT06374342

Intervention type: DEVICE
Intervention: Bone defect
Description: Bone grafting is a procedure where damaged bones can be repaired or rebuilt using transplanted bone from another source. Sources for transplant bone include the patient (autograft), a cadaver (allograft) or synthetic bone.

Intervention type: DEVICE
Intervention: Bone defect
Description: Bone grafting is a procedure where damaged bones can be repaired or rebuilt using transplanted bone from another source. Sources for transplant bone include the patient (autograft), a cadaver (allograft) or synthetic bone.

Intervention type: DEVICE
Intervention: Bone defect
Description: Bone grafting is a procedure where damaged bones can be repaired or rebuilt using transplanted bone from another source. Sources for transplant bone include the patient (autograft), a cadaver (allograft) or synthetic bone.

Intervention type: DEVICE
Intervention: Bone defect
Description: Bone grafting is a procedure where damaged bones can be repaired or rebuilt using transplanted bone from another source. Sources for transplant bone include the patient (autograft), a cadaver (allograft) or synthetic bone.

Intervention type: DEVICE
Intervention: Bone defect
Description: Bone grafting is a procedure where damaged bones can be repaired or rebuilt using transplanted bone from another source. Sources for transplant bone include the patient (autograft), a cadaver (allograft) or synthetic bone.

Intervention type: DEVICE
Intervention: Spine fusion
Description: Spinal fusion is a surgery procedure that reinforces your back structure and stability by linking two vertebrae together

Intervention type: DEVICE
Intervention: Spine fusion
Description: Spinal fusion is a surgery procedure that reinforces your back structure and stability by linking two vertebrae together
Study: NCT05700916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Polar Lipid-Rich Dairy Powder
Description: Effects of the addition of 6.5 g of milk polar lipids to dairy powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dairy Powder
Description: Effects of dairy control powder
Study: NCT06374342

Intervention type: DEVICE
Intervention: Cage filling
Description: Intervertebral fusion with cages is a surgical procedure used to stabilize the spine by fusing adjacent vertebrae. The cages, typically made of materials like titanium or plastic, and pre-filled with bone graft substitutes are placed between the vertebrae to maintain the proper spacing and alignment.
Study: NCT05161143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: Donafenib: 4-8 weeks after radical surgery,patients will take donafenib, 200mg Bid,at least 6 months.~TACE:4-8 weeks after radical surgery,patients will receive TACE once.
Study: NCT05972733

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIL-214
Description: HIL-214
Study: NCT05388994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The initial implementation for the 8-week combined exercise program consisted of a progressive aerobic exercise program with a lower extremity bike (Ergoline Ergoselect 200; Ergoline GMBH, Bitz, Germany). All sessions are individually supervised and conducted. Training intensity was started at 70% of maximum aerobic capacity and training intensity was increased by 5% of VO2peak every two weeks. Pedal speed was fixed at 50 rpm throughout 8 weeks of training. Exercise sessions; It started with a 5 minute warm-up period (30% of VO2peak), followed by a total of 40 minutes with a 30-minute load period and a 5-minute cool-down period (without resistance).
Study: NCT05817669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Description: Patients receiving efgartigimod infusions

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receiving placebo infusions
Study: NCT06437080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron III Hydroxide Polymaltose Complex eq. to Elemental Iron, 100 mg
Description: 01 tablet daily for 03 months, This is assigned to Group A.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose
Description: 03 doses (50 mg iron/mL) per month for 03 months. This is assigned to Group B.
Study: NCT06077565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot-in-the-door technique and self-determination theory
Description: the research assistant will ask about the priority the participants place on engagement in desirable health-related lifestyle practices identified in the completed behavioural risk factor survey. The participants will also be asked to choose the goal that they consider easiest to achieve, such as quitting or reducing smoking, consuming more vegetables or less fatty foods or sugary drinks, performing more exercise or reducing alcohol consumption. The participants will be encouraged to quit health-risk behaviours (or adopt a healthy lifestyle) sequentially, but they will also be able to choose to quit them simultaneously if they are confident in doing so. Each participant will then receive a brief (approximately 5 minutes), individual intervention with health advice about the selected health-related lifestyle practice. The whole intervention will last approximately 10 minutes, but slightly longer if necessary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up booster intervention
Description: For the first 6 months of the study period, the research assistant will deliver WhatsApp/WeChat messages about once per week. If a participant does not own a smartphone or is unable to receive WhatsApp/WeChat messages (uncommon in Hong Kong), the research assistant will make a telephone call, instead of sending a message, as a reminder for the participants to adhere to their desirable health-related lifestyle practice. Instant messaging via mobile applications has found to be effective in enhancing treatment compliance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The control group participants will receive a brief telephone intervention based on the AWARD model and delivered by the trained research assistant, similar to that delivered to the intervention group. However, the research assistant will simply advise the participants to change their health-risk behaviours and/or adopt a healthy lifestyle practice.
Study: NCT05716789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPR
Description: CPR in cardiac arrest patients
Study: NCT05197712

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25 Baiya SARS-CoV-2 Vax 2
Description: Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 2 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 Baiya SARS-CoV-2 Vax 2
Description: Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 2 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
Study: NCT05163509

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Unity-based MR-Linac guided Radiotherapy
Description: The radiotherapy was delivered using the Unity-based MR-Linac treatment machine.
Study: NCT05040685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary mapping reverse
Description: At the time of performing the ALND associate the ARM, injecting between 2-5mL of indocyanine green subcutaneously in the ipsilateral upper extremity at the medial inter-muscular and massaged for 5 min. First, identify the ARM nodes by indocyanine green, then perform conventional axillary lymphadenectomy trying to preserve the ARM nodes. And, in a second time, extract ARM nodes for their individualized anatomopathological study.
Study: NCT04932824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCB-2019
Description: a Recombinant SARS-CoV-2 Trimeric S-Protein Subunit Vaccine for COVID-19.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCB-2019
Description: a Recombinant SARS-CoV-2 Trimeric S-Protein Subunit Vaccine for COVID-19.
Study: NCT04216589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Administered subcutaneously
Study: NCT05015621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surufatinib plus Toripalimab
Description: Surufatinib is a tablet in the form of 50mg, oral, once a day; Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: 5-fluorouracil, Calcium folinate and Irinotecan
Description: Irinotecan 180 mg/m\^2, Calcium folinate 400 mg/m\^2, 5-FU total 2800 mg/m\^2 will be administrated once two weeks.
Study: NCT04933916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMB-001
Description: Combination product metyrapone and oxazepam
Study: NCT05002959

Intervention type: DEVICE
Intervention: Anatomic TESS V3
Description: Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Anatomic configuration.

Intervention type: DEVICE
Intervention: Reverse TESS V3
Description: Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Reverse configuration.